Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-11 5:24 pm Purchase | 2026-03-10 | 13G | Korro Bio, Inc. KRRO | Point72 Asset Management, L.P. | 816,885 5.700% | 540,054 (+195.08%) | Filing History |
| 2026-03-10 6:41 pm Sale | 2025-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | Point72 Asset Management, L.P. | 1,758,357 2.600% | -2,706,043 (-60.61%) | Filing History |
| 2026-03-03 4:25 pm Purchase | 2026-02-24 | 13G | Edesa Biotech, Inc. EDSA | Point72 Asset Management, L.P. | 600,000 7.200% | 600,000 (New Position) | Filing History |
| 2026-02-23 6:09 pm Purchase | 2026-02-18 | 13G | Beta Bionics, Inc. BBNX | Point72 Asset Management, L.P. | 2,290,023 5.200% | 2,290,023 (New Position) | Filing History |
| 2026-02-19 4:59 pm Purchase | 2026-02-17 | 13G | Q32 Bio Inc. QTTB | Point72 Asset Management, L.P. | 2,057,308 9.900% | 2,057,308 (New Position) | Filing History |
| 2026-02-18 5:42 pm Purchase | 2026-02-17 | 13G | OKYO Pharma Limited OKYO | Point72 Asset Management, L.P. | 4,058,445 7.900% | 4,058,445 (New Position) | Filing History |
| 2026-02-17 4:36 pm Purchase | 2025-12-23 | 13G | Century Therapeutics, Inc. IPSC | Point72 Asset Management, L.P. | 5,961,563 6.800% | 1,235,924 (+26.15%) | Filing History |
| 2026-02-17 4:35 pm Purchase | 2025-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH | Point72 Asset Management, L.P. | 2,981,674 6.900% | 860,534 (+40.57%) | Filing History |
| 2026-02-17 4:35 pm Sale | 2025-12-31 | 13G | Kodiak Sciences Inc. KOD | Point72 Asset Management, L.P. | 2,166,929 3.500% | -741,907 (-25.51%) | Filing History |
| 2026-02-17 4:34 pm Sale | 2025-12-31 | 13G | Wolfspeed, Inc. WOLF | Point72 Asset Management, L.P. | 990,150 3.800% | -555,837 (-35.95%) | Filing History |
| 2026-02-17 4:34 pm Sale | 2025-12-31 | 13G | ADC Therapeutics S.A. ADCT | Point72 Asset Management, L.P. | 5,014,617 4.000% | -2,816,808 (-35.97%) | Filing History |
| 2026-02-17 4:33 pm Sale | 2025-12-31 | 13G | Verastem, Inc. VSTM | Point72 Asset Management, L.P. | 995,026 1.300% | -2,343,393 (-70.19%) | Filing History |
| 2026-02-17 4:33 pm Sale | 2025-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | Point72 Asset Management, L.P. | 627,502 3.500% | -426,481 (-40.46%) | Filing History |
| 2026-02-17 4:32 pm Sale | 2025-12-31 | 13G | Confluent, Inc. CFLT | Point72 Asset Management, L.P. | 183,700 0.100% | -17,348,113 (-98.95%) | Filing History |
| 2026-02-17 4:32 pm Sale | 2025-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | Point72 Asset Management, L.P. | 450,000 1.400% | -1,128,069 (-71.48%) | Filing History |
| 2026-02-17 4:31 pm Sale | 2025-12-31 | 13G | FG Nexus Inc. FGNX | Point72 Asset Management, L.P. | 0 0.000% | -4,000,000 (Position Closed) | Filing History |
| 2026-02-17 4:31 pm Sale | 2025-12-31 | 13G | Praxis Precision Medicines, Inc. PRAX | Point72 Asset Management, L.P. | 1,569,309 6.100% | -503,640 (-24.30%) | Filing History |
| 2026-02-17 4:30 pm Sale | 2025-12-31 | 13G | PagSeguro Digital Ltd. PAGS | Point72 Asset Management, L.P. | 5,989,393 3.800% | -4,157,759 (-40.97%) | Filing History |
| 2026-02-17 4:30 pm Purchase | 2025-12-31 | 13G | Alto Neuroscience, Inc. ANRO | Point72 Asset Management, L.P. | 2,824,275 8.900% | 916,444 (+48.04%) | Filing History |
| 2026-02-17 4:29 pm Sale | 2025-12-31 | 13G | Korro Bio, Inc. KRRO | Point72 Asset Management, L.P. | 276,831 2.900% | -540,074 (-66.11%) | Filing History |